Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.
about
Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemiaPseudo-Cyclization through Intramolecular Hydrogen Bond Enables Discovery of Pyridine Substituted Pyrimidines as New Mer Kinase InhibitorsThe Receptor Tyrosine Kinase AXL in Cancer ProgressionCabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experienceParadoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancerUNC1062, a new and potent Mer inhibitor.Axl acts as a tumor suppressor by regulating LIGHT expression in T lymphoma.Axl tyrosine kinase protects against tubulo-interstitial apoptosis and progression of renal failure in a murine model of chronic kidney disease and hyperphosphataemia.TAM receptor tyrosine kinases: expression, disease and oncogenesis in the central nervous system.Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapiesProlonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus.AXL mediates resistance to cetuximab therapyDirect regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.Gene expression profiles of the NCI-60 human tumor cell lines define molecular interaction networks governing cell migration processesGlycoxidised LDL induced the upregulation of Axl receptor tyrosine kinase and its ligand in mouse mesangial cells.GAS6 receptor status is associated with dormancy and bone metastatic tumor formationRedundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcomaFlow cytometry-based functional selection of RNA interference triggers for efficient epi-allelic analysis of therapeutic targets.Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells.TAM receptor signaling in immune homeostasis.Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancerAXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas.Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.Systematic identification of the HSP90 candidate regulated proteome.Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancerAxl-dependent signalling: a clinical update.TAM receptors in leukemia: expression, signaling, and therapeutic implications.Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivoSynthesis, biological evaluation, and physicochemical property assessment of 4-substituted 2-phenylaminoquinazolines as Mer tyrosine kinase inhibitorsMerTK inhibition in tumor leukocytes decreases tumor growth and metastasisUNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivoPreclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients.AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.Imaging Axl expression in pancreatic and prostate cancer xenografts.Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.Reversal of Cisplatin resistance by epigallocatechin gallate is mediated by downregulation of axl and tyro 3 expression in human lung cancer cells.Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update.
P2860
Q24311970-5880BB18-ED57-4E38-8388-8C94BC814877Q27680540-99E5DDF1-5C4E-4FE4-B0B4-545BB282F22EQ28068756-9ABAA7AB-8CD0-4D86-8C5A-B1C882996C58Q28072166-2427A8BD-6510-49ED-8D3F-83015638DCAEQ28588141-54FCD3FA-529C-4254-AA2B-70D5ED837FE1Q30630130-0F5FA826-4764-4458-BA05-E60590B32275Q33591281-E433FB59-C2EB-4F16-A5B4-6E73F785668BQ33897354-43BB48FB-761E-44CB-9EE7-79753C2B3C80Q34077622-D2CED739-E7B5-47D2-BC1C-629FE317A792Q34158454-DFF07BA2-A637-4CA2-9C2E-C191CA84E891Q34171209-CA84C8F3-D2EB-49EA-AB70-E83E9D8E9BDBQ34204829-4D84ADBE-B79E-4864-965C-A48D779F3F04Q34217927-87DA6204-FBD0-4A99-9A29-D159FAC827CAQ34263230-8DF35E1D-BA9A-4180-9719-BB11CF88CA04Q34505237-C3616B76-C48A-4BFF-BC0E-292DEC9CD13AQ34700694-4CA9D487-0BBD-4529-B042-0342CA74ACB8Q34704781-C2A62F19-93B0-4637-8641-63B05B5CC246Q35149569-058C1704-ECFD-458B-9FA3-BBEE4E6EC652Q35192741-5D8361E0-60AB-4F36-9A4B-BA05EDA1204BQ35677075-FA596BC0-7EAF-40E1-A3FF-8D496F24B08DQ35819380-A9A49EED-FE86-44D6-8818-4395200A03C9Q35832938-494956C3-F6B6-4A8B-A340-4AC0E50AFB56Q35843071-07336982-C686-43F0-9E02-8F5A0B5FD7F0Q36128435-E8D03A90-7172-47CF-97F1-0A00487F37BCQ36209058-38F669C9-FC59-40A4-A118-8F0F328372B3Q36413157-C5AF8297-DC37-4D97-950C-AB54FB48E8FBQ36720080-13DE41CD-9DC2-4B88-8367-FB6F6939E133Q36865209-B7E6002A-C13B-4417-8923-A48474FC5709Q36962825-FDEB667A-AEC8-42E4-A770-1A7C98F2DF4EQ37036648-9B1BFB08-C3D9-4A7D-8DD3-B93C340B4381Q37052927-5F3A4D10-9CF7-4E82-AFD0-FBCE4265198DQ37297144-08A7861B-EA6C-43D0-800E-5654BD2B271BQ37321961-7D149B72-1D8C-4E9A-916D-A7E1A4B70EFAQ37369038-DFB45103-1FFA-4DF8-8695-3A1871DA38C6Q37451822-1ABDF766-42CA-4009-BF9C-5D205298A4CBQ37571724-AD87B35C-8FE7-4EA4-A19B-07D9C47DA81FQ37955105-324F9045-34B8-49DD-AAAD-657B962AF02BQ38214511-F42D2001-4113-4A90-8C8B-53B20B8A48B1Q38261470-79055E53-CF87-4CA4-A896-5A113CC1889DQ38669280-0B0EFEE9-6A1D-4E51-8EC0-32FDB80DB468
P2860
Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Taking aim at Mer and Axl rece ...... eutic targets in solid tumors.
@ast
Taking aim at Mer and Axl rece ...... eutic targets in solid tumors.
@en
type
label
Taking aim at Mer and Axl rece ...... eutic targets in solid tumors.
@ast
Taking aim at Mer and Axl rece ...... eutic targets in solid tumors.
@en
prefLabel
Taking aim at Mer and Axl rece ...... eutic targets in solid tumors.
@ast
Taking aim at Mer and Axl rece ...... eutic targets in solid tumors.
@en
P2093
P2860
P1476
Taking aim at Mer and Axl rece ...... eutic targets in solid tumors.
@en
P2093
Amy K Keating
Douglas K Graham
H Shelton Earp
Rachel M A Linger
P2860
P304
P356
10.1517/14728222.2010.515980
P407
P577
2010-10-01T00:00:00Z